The impact of the distribution of human papillomavirus types and associated high-risk lesions in a colposcopy population for monitoring vaccine efficacy

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 1, 2008, Pages 54-60

  Antonishyn, Nick A ^a,b   Horsman, Greg B ^b   Kelln, Rod A ^a   Saggar, Jasdeep ^c   Severini, Alberto ^c  

^a UNIVERSITY OF REGINA   (Canada)

^b Saskatchewan Disease Control Laboratory   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANADA; CANCER RISK; COLPOSCOPY; CORRELATION ANALYSIS; DNA SEQUENCE; DRUG EFFICACY; DRUG MONITORING; FEMALE; GENE E1; GENOTYPE; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN TISSUE; L1 GENE; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; TECHNOLOGY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS GENE; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 38049044978     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. de Villiers E, Fauquet C, Broker T, Bernard H, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27.
2. van den Brule A, Meijer C, Bakels V, Kenemans P, Walboomers J. Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol. 1990;28:2739-2743.
3. Hindryckx P, Garcia A, Claeys P, et al. Prevalence of high risk human papillomavirus types among Nicaraguan women with histological proved pre-neoplastic and neoplastic lesions of the cervix. Sex Transm Infect. 2006;82:334-336.
4. Burd E. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1-17.
5. Bosch F, Sanjose S, Castellsague X, Moreno V, Munoz N. Epidemiology of human papillomavirus infections and associations with cervical cancer: new opportunities for prevention. In: Campo M, ed. Papillomavirus Research: From Natural History to Vaccines and Beyond. Norfolk, England: Caister Academic Press; 2006:19-40.
6. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3-8.
7. Parkin D, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
8. Arends M, Buckley C, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol. 1998;51:96-103.
9. Clavel C, Masure M, Bory J, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001;84:1616-1623.
10. Walboomers J, Jacobs M, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
11. Munoz N, Bosch F, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
12. Severson J, Evans T, Lee P, Chan T, Arany I, Tyring S. Human papillomavirus infections: epidemiology, pathogenesis, and therapy. J Cutan Med Surg. 2001;5:43-60.
13. Syrjanen S, Syrjanen K. New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med. 1999;31:175-187.
14. Southern S, Herrington C. Disruption of cell cycle control by human papillomaviruses with special reference to cervical carcinoma. Int J Gynecol Cancer. 2000;10:263-274.
15. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690-698.
16. Hebner C, Laimins L. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006;16:83-97.
17. Clifford G, Callus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991-998.
18. Siddiqui M, Perry C. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 2006;66:1263-1271; discussion 1272-1273.
19. Villa L. Efficacy of a quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against cervical intraepithelial neoplasia grades 1-3 and adenocarcinoma in situ: a combined analysis [published online August 28, 2006]. Eur J Obstet Gynecol Reprod Biol. In press, corrected proof. Available at: http://www.sciencedirect.com.
20. Dunne E, Markowitz L. Genital human papillomavirus infection. Clin Infect Dis. 2006;43:624-629.
21. Harper D, Franco E, Wheeler C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
22. Harper D, Franco E, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
23. Daily P. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54:893-897.
24. de Roda Husman A, Walboomers J, van den Brule A, Meijer C, Snijders P. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76:1057-1062.
25. Ylitalo N, Bergstrom T, Gyllensten U. Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization. J Clin Microbiol. 1995;33:1822-1828.
26. Strauss S, Jordens J, McBride D, et al. Detection and typing of human papillomavirus DNA in paired urine and cervical scrapes. Eur J Epidemiol. 1999;15:537-543.
27. Schmitt M, Bravo I, Snijders P, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 2006;44:504-512.
28. Wang-Johanning F, Lu D, Wang Y, Johnson M, Johanning G. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer. 2002;94:2199-2210.
29. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer. 2006;16:1017-1024.
30. Wheeler CM, Hunt WC, Schiffman M, Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194:1291-1299.
31. Chan P, Cheung T, Tarn A, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer. 2006;118:243-245.
32. Weiler SC, Stanberry LR. Estimating the population prevalence of HPV. JAMA. 2007;297:876-878.
33. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
34. Beerens E, Van Renterghem L, Praet M, et al. Human papillomavirus DNA detection in women with primary abnormal cytology of the cervix: prevalence and distribution of HPV genotypes. Cytopathology. 2005;16:199-205.
35. Rassu M, Bertoloni G, Mengoli C, Peron A, Benedetti P, PaLu' G. HPV genotype prevalence in cervical specimens with abnormal cytology: a report from north-east Italy. Scand J Infect Dis. 2005;37:476-481.
36. Clifford GM, Rana RK, Franceschi S, Smith JS, Cough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157-1164.
37. Camara GN, Cerqueira DM, Oliveira AP, Silva EO, Carvalho LG, Martins CR. Prevalence of human papillomavirus types in women with pre-neoplasticand neoplastic cervical lesions in the Federal District of Brazil. Mem Inst Oswaldo Cruz. 2003;98:879-883.
38. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol. 2006;101:40-45.
39. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol. 1996;34:2095-2100.
40. Quint WG, Pagliusi SR, LeNe N, de Villiers EM, Wheeler CM. Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol. 2006;44:571-579.
41. Angulo M, Carvajal Rodriguez A. Evidence of recombination within human alpha-papillomavirus. Virol J. 2007;4:33.
42. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
43. Shah KV, Kessis TD, Shah F, Gupta JW, Shibata D, Jones RW. Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer. Int J Gynecol Pathol. 1996;15:127-130.
44. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079.
45. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632.